Endocrinology

Sulfonylurea and/or insulin deintensification occurred in fewer than 50% of older adults with diabetes within 100 days of a hypoglycemia-associated ED visit.

An imaging study of girls with idiopathic CPP and matched controls suggests idiopathic CPP was associated with increased gray matter and white matter volumes in the cerebral area.

Using data from more than 50 women, investigators determined exposure to GnRHa treatment was not associated with an increased risk of developing PCOS in women with CPP treated with GnRHa.

Results of a recent study provide insight into the prevalence of rare sequence variants among the MKRN3, DLK1, KISS1, and KISS1R genes in children with CPP.

Mount Sinai-led chart review provides insight into the influence of various factors on time to menarche among girls with central precocious puberty who received GnRHa treatment.

A cross-sectional study has returned results that suggest a risk score model could help identify patients with central precocious puberty without the need for more expensive and invasive stimulation tests.

A systematic review and meta-analysis detail the effects of GnRHa therapy on final adult height, BMI, risk of PCOS, and more long-term outcomes among patients with idiopathic CPP.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

Our latest emergency department quiz from Brady Pregerson, MD, features a woman in her 40’s presenting with 3 days of generalized malaise and worsening left buttock pain with subjective fevers. Check out the CT and see if you can determine the correct diagnosis.

An analysis of data from multiple Danish registries provides evidence suggesting women who experience preterm delivery had 1.6-fold greater odds of developing hypertension later in life.

Data show In youth with obesity, but not healthy weight, visceral fat was positively associated with PWV and was predictive of PWV beyond BMI and waist circumference.

In older patients receiving medication intensification, no differences were seen in the risk of severe hyperglycemia, severe hypoglycemia, or death at 1 year.

Muthiah Vaduganathan, MD, MPH, presents a case study for a patient hospitalized with heart failure whose therapy was optimized with an SGLT-2 inhibitor.

A panel of experts provide clinical pearls for primary care providers who manage patients with diabetes and cardiovascular comorbidities.

Robert Busch, MD, provides an overview of the clinical trials supporting improved cardiovascular disease outcomes in patients with and without diabetes.

A panel of experts discuss their experience with multidisciplinary collaboration of care between primary care physicians, cardiologists, endocrinologists, and pharmacists in patients with diabetes and cardiovascular disease.

Muthiah Vaduganathan, MD, MPH, provides insight into cardiology guidelines for the use of SGLT-2 [sodium-glucose cotransporter-2] inhibitors and GLP-1 [glucagon-like peptide-1] receptor agonists and discusses the uptake of these medications in patients with and without diabetes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discusses goals of therapy in diabetic patients with cardiovascular disease and Robert Busch, MD, provides an overview of diabetes treatment guidelines.

Dhiren Patel, PharmD, CDE, BC-ADM, BCACP; Robert Busch, MD; and Muthiah Vaduganathan, MD, MPH, provide an overview of cardiovascular comorbidities in patients with diabetes.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, presents a case study of a patient with type 2 diabetes mellitus, an insulin pump, and a continuous glucose monitor.

Experts in diabetes discuss the transition to telemedicine during the COVID-19 pandemic and its impact on diabetes care.

Dhiren Patel, PharmD, CDE, BC-ADM, BCACP; Robert Busch, MD; and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, provide insight into quality-of-life improvements that have followed advances in diabetes technology and review available continuous glucose monitors.

Robert Busch, MD, and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discuss metrics to evaluate diabetes control, including time in range and coefficient of variation.

A panel of experts discuss the impact of continuous glucose monitoring (CGM) on individualized patient care plans for patients with type 1 and type 2 diabetes.

Robert Busch, MD, and Diana Issacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, provide insight into the use of insulin pumps in type 2 diabetes and describe currently available smart pumps.

Experts in diabetes discuss recent advances in insulin pen technology, including connected and smart pens, and their impact on diabetes care.

Dhiren Patel, PharmD, CDE, BC-ADM, BCACP; Robert Busch, MD; and Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, provide an overview of the pillars of technology utilized in diabetes care: Continuous glucose monitors (CGMs), smart insulin pumps, and connected insulin pens.

The mean IR of first registered DFU was 2.5 per 1000 person-years for patients with T2D and 1.6 per 1000 person-years for patients with T1D.

An analysis of more than 2.4 million offspring in Denmark suggests children with exposure to maternal diabetes during pregnancy were at a 15% greater risk of developing a psychiatric disorder in the first 40 years of life.

Using data from SWAN DHS, investigators determined changes in menstrual cycle length prior to a woman's final menstrual period were associated with changes in carotid intima-media thickness and brachial-ankle pulse wave velocity.